Warren Olanow News Today

EAST ST. LOUIS - After an expert witness for plaintiffs claiming weed killer paraquat caused Parkinson's disease testified to attributing 74% of the weight of his causation opinion on one study, the plaintiffs explain a shortage of research by accusing manufacturer Syngenta of corrupting science in general and the U.S. Environmental Protection Agency (EPA) in particular.

/PRNewswire/ -- Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, will...

ND0612, a continuous 24 hours/day subcutaneous (SC) infusion?of liquid levodopa/carbidopa (LD/CD), showed superior efficacy compared to oral LD/CD for the primary endpoint ("ON" time without

An experimental drug that combines low-dose extended-release pramipexole and rasagiline showed strong efficacy in early-stage Parkinsons disease — with less sleepiness — in a new phase 3 trial.

The novel drug P2B001 is superior to its individual components of pramipexole or rasagiline for early Parkinsons disease ― with less daytime sleepiness, new topline results suggest.

/PRNewswire/ -- Pharma Two B Ltd., a privately held company developing innovative therapeutics based on reformulation and combinations of previously approved...

/PRNewswire/ -- Pharma Two B Ltd., a privately held company developing innovative therapeutics based on reformulation and combinations of previously approved...

/PRNewswire/ -- Pharma Two B Ltd., a privately held company developing innovative therapeutics based on reformulation and combinations of previously approved...

Study successfully met its primary and key secondary endpoints, demonstrating superior efficacy of P2B001 compared to its individual components P2B001 showed comparable efficacy to a marketed

/PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to...